Zobrazeno 61 - 70
of 84
pro vyhledávání: '"329"'
Autor:
Joseph Pidala, Mukta Arora, Paul J. Martin, Xiaoyu Chai, Barry E. Storer, Jeanne Palmer, Madan Jagasia, Mary E.D. Flowers, Corey Cutler, Stephanie J. Lee, Sally Arai, Yoshihiro Inamoto, Steven Z. Pavletic, Georgia B. Vogelsang, Daniel J. Weisdorf
Publikováno v:
Blood. 122:4614-4614
The global severity score (GS) was devised by experts during the 2005 NIH Consensus for chronic graft-versus-host disease (GVHD) to reflect the overall severity of chronic GVHD at any time point. According to this scale, overall involvement is catego
Autor:
Kara Cetin, Michelle Gleeson, Robert I. Griffiths, Aaron J. Katz, Michael A. Kelsh, Mark D. Danese
Publikováno v:
Blood. 122:3877-3877
Background ALL is the most common childhood cancer, with remission rates exceeding 90% and 5-year survival exceeding 80% in pediatric patients. However, in older adult patients, ALL is associated with high morbidity and mortality. Nonetheless, becaus
Autor:
Shaji Kumar, Sagar Lonial, Suzanne Trudel, Paul G. Richardson, David S. Siegel, Keith Stewart, Martin H. van Vliet, Kenneth C. Anderson, Andrzej Jakubowiak, Donna E. Reece, Sundar Jagannath, Ravi Vij, Rafael Fonseca, Erik H. van Beers, Todd M. Zimmerman, Joan Levy, Ajai Chari, Daniel Lebovic
Publikováno v:
Blood. 122:1854-1854
Introduction Multiple Myeloma is not a single disease. There is increasing support for risk classification in combination with treatment decision making because of its impact on clinical outcomes. Here we demonstrate additional evidence of the progno
Autor:
Ajay K. Nooka, Jonathan L. Kaufman, Nishi N Shah, Bilal Hassan, Lawrence H. Boise, Ifor Williams, Sagar Lonial
Publikováno v:
Blood. 122:3148-3148
Background Heavy light chain (HLC) assays allow for accurate quantification of involved and uninvolved immunoglobulins (Ig) of the affected isotype. HLC ratio is of particular interest in measuring low level disease where there is limited utility for
Autor:
Rudy Chapusette, Laurence Dedeken, Phu-Quoc Le, Catherine Heijmans, Christine Devalck, Sophie Huybrechts, France Ziereisen, Laurence Hanssens, Malou Ngalula, Alina Ferster
Publikováno v:
Blood. 120:2107-2107
2107 [][1] The 6-minute walk test (6MWT) evaluates the sub-maximal functional exercise capacity and can be used together with the tricuspid regurgitant jet velocity (TRV) and pro-BNP to screen pulmonary hypertension in adults with sickle cell disease
Autor:
Jean-Philippe Galanaud, Isabelle Quéré, Jean-Luc Bosson, Anne-Cecile Arnoult, Céline Genty, Marie-Antoinette Sevestre
Publikováno v:
Blood. 120:630-630
Abstract 630 Background: Cancer constitutes a strong risk factor for proximal deep-vein thrombosis (DVT). After a proximal DVT, the risk of being diagnosed a previously undiagnosed cancer in the following years is high. This has justified a cancer sc
Autor:
Matthew B. Siegel, Patrick J. Stiff, Aileen Go, Tulio E. Rodriguez, Brian Hess, Maria Theodorou, Michael Tallarico, Shams Bakhos, Scott E. Smith
Publikováno v:
Blood. 120:3102-3102
Abstract 3102 Identifying the optimal patients and timing for allogeneic hematopoietic stem cell transplant (HSCT) is an ongoing challenge for transplant centers that requires assessment of more than just the disease status and stage. Pre-existing co
Autor:
Heinz Haverkamp, Peter Borchmann, Jana Markova, Zdenek Kral, Andreas Engert, Carsten Kobe, Hans Theodor Eich, Josée M. Zijlstra, Anthony D. Ho, Harald Stein, Rolf-Peter Müller, Christoph Renner, Markus Dietlein, Volker Diehl
Publikováno v:
Blood. 118:589-589
Abstract 589FN2 Purpose: Intensified chemotherapy with eight cycles of BEACOPPescalated in advanced stage Hodgkin lymphoma (HL) is highly effective but also associated with relevant treatment related toxicity. In addition, the need for radiotherapy i
Autor:
Neeraj Agarwal, Jason Li, Nicole Hagner, Margaret M. Woo, Martijn P. Lolkema, Sunil Sharma, Emile E. Voest, Petronella O. Witteveen, Maria Grazia Porro, Dagmar Hess, Derek Mires, Sue-zette Valera
Publikováno v:
Blood. 118:5001-5001
Abstract 5001 Panobinostat is a potent class I/II/IV oral pan-deacetylase inhibitor which has shown promising clinical activity in patients with multiple myeloma and myelofibrosis, some with compromised renal and hepatic functions. The metabolism med
Autor:
Hagop M. Kantarjian, Jorge E. Cortes, Mahran Shoukier, Zeev Estrov, Susan O'Brien, Elizabeth M. Burton, Tapan M. Kadia, Elias Jabbour, Steven M. Kornblau, Guillermo Garcia-Manero, Alfonso Quintás-Cardama, Gautam Borthakur
Publikováno v:
Blood. 118:2764-2764
Abstract 2764 Background: Nilotinib is accepted standard of care for CP-CML as initial therapy or after resistance or intolerance to imatinib. Nilotinib increases blood sugar level in diabetic and non-diabetic patients. This has caused concern about